1. Home
  2. COGT vs COLL Comparison

COGT vs COLL Comparison

Compare COGT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • COLL
  • Stock Information
  • Founded
  • COGT 2014
  • COLL 2002
  • Country
  • COGT United States
  • COLL United States
  • Employees
  • COGT N/A
  • COLL N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • COGT Health Care
  • COLL Health Care
  • Exchange
  • COGT Nasdaq
  • COLL Nasdaq
  • Market Cap
  • COGT 806.1M
  • COLL 958.8M
  • IPO Year
  • COGT 2018
  • COLL 2015
  • Fundamental
  • Price
  • COGT $7.41
  • COLL $30.51
  • Analyst Decision
  • COGT Buy
  • COLL Strong Buy
  • Analyst Count
  • COGT 6
  • COLL 4
  • Target Price
  • COGT $15.20
  • COLL $43.75
  • AVG Volume (30 Days)
  • COGT 2.4M
  • COLL 282.0K
  • Earning Date
  • COGT 08-05-2025
  • COLL 08-07-2025
  • Dividend Yield
  • COGT N/A
  • COLL N/A
  • EPS Growth
  • COGT N/A
  • COLL N/A
  • EPS
  • COGT N/A
  • COLL 1.25
  • Revenue
  • COGT N/A
  • COLL $664,283,000.00
  • Revenue This Year
  • COGT N/A
  • COLL $20.04
  • Revenue Next Year
  • COGT N/A
  • COLL $3.98
  • P/E Ratio
  • COGT N/A
  • COLL $24.37
  • Revenue Growth
  • COGT N/A
  • COLL 17.17
  • 52 Week Low
  • COGT $3.72
  • COLL $23.23
  • 52 Week High
  • COGT $12.61
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • COGT 64.24
  • COLL 60.67
  • Support Level
  • COGT $7.07
  • COLL $29.28
  • Resistance Level
  • COGT $7.50
  • COLL $30.83
  • Average True Range (ATR)
  • COGT 0.43
  • COLL 0.73
  • MACD
  • COGT -0.06
  • COLL 0.01
  • Stochastic Oscillator
  • COGT 55.94
  • COLL 81.71

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: